Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Summary

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Eligibility

Inclusion Criteria:

* Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation
* Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage
* ECOG performance status 0 or 1
* Adequate organ function

Exclusion Criteria:

* Primary central nervous system (CNS) tumors
* Known or suspected leptomeningeal or active brain metastases or spinal cord compression
* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
* Participant was previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors)

Other inclusion/exclusion criteria may apply.

Conditions6

Interventions2

Locations17 sites

Find trials near these locations

Related trials

• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors — Revolution Medicines, Inc.
• Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC — Revolution Medicines, Inc.
• Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients — Tango Therapeutics, Inc.
• A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) — Amgen
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS — Revolution Medicines, Inc.

Browse More Trials